Free Trial

Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

$0.40
+0.01 (+2.56%)
(As of 10/15/2024 ET)

Unicycive Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
5

Based on 5 Wall Street analysts who have issued ratings for Unicycive Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 4 have given a buy rating, and 1 has given a strong buy rating for UNCY.

Consensus Price Target

$5.13
1,181.25% Upside
According to the 5 analysts' twelve-month price targets for Unicycive Therapeutics, the average price target is $5.13. The highest price target for UNCY is $9.00, while the lowest price target for UNCY is $2.50. The average price target represents a forecasted upside of 1,181.25% from the current price of $0.40.
Get the Latest News and Ratings for UNCY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Unicycive Therapeutics and its competitors.

Sign Up

UNCY Analyst Ratings Over Time

TypeCurrent Forecast
10/16/23 to 10/15/24
1 Month Ago
9/16/23 to 9/15/24
3 Months Ago
7/18/23 to 7/17/24
1 Year Ago
10/16/22 to 10/16/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$5.13$5.13$5.63$10.83
Forecasted Upside1,181.25% Upside1,197.47% Upside1,181.32% Upside1,205.22% Upside
Consensus Rating
Buy
Buy
Buy
Buy

UNCY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

UNCY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Unicycive Therapeutics Stock vs. The Competition

TypeUnicycive TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.20
2.79
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside1,181.25% Upside10,342.64% Upside6.70% Upside
News Sentiment Rating
Neutral News

See Recent UNCY News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/9/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$2.50 ➝ $2.50+587.93%
9/6/2024Benchmark
2 of 5 stars
B. Jackson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.00+749.12%
7/9/2024Brookline Capital Management
3 of 5 stars
K. Raja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/4/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$9.00+556.93%
2/14/2024Noble Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$6.00+445.50%
7/3/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$6.00 ➝ $4.00+212.50%
4/6/2023Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Raja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
3/31/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$24.00+1,118.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:12 PM ET.


UNCY Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Unicycive Therapeutics is $5.13, with a high forecast of $9.00 and a low forecast of $2.50.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unicycive Therapeutics in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" UNCY shares.

According to analysts, Unicycive Therapeutics's stock has a predicted upside of 1,181.25% based on their 12-month stock forecasts.

Unicycive Therapeutics has been rated by research analysts at Benchmark, and HC Wainwright in the past 90 days.

Analysts like Unicycive Therapeutics more than other "medical" companies. The consensus rating for Unicycive Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how UNCY compares to other companies.


This page (NASDAQ:UNCY) was last updated on 10/15/2024 by MarketBeat.com Staff
From Our Partners